印度第一种本土登革热疫苗Deniall开始第三阶段试验。 India's first indigenous dengue vaccine, DengiAll, commences phase III trials.

印度首个本土登革热疫苗Deniall由Panacea生物技术开发, 已开始在罗塔克的Pandit Bhagwat Dayal Sharma研究生医学院进行第三阶段临床试验。 India's first indigenous dengue vaccine, DengiAll, developed by Panacea Biotech, has commenced phase III clinical trials at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak. 审判将在18个州和联盟领土的19个地点进行,涉及10 335名健康成年人。 The trial will take place at 19 sites across 18 states and union territories, involving 10,335 healthy adults. 疫苗针对所有四种登革热血清型,由印度医学研究理事会赞助。 The vaccine targets all four serotypes of dengue and is sponsored by the Indian Council of Medical Research. 这标志着在防治登革热方面迈出了重要一步,突出了印度在疫苗研发方面的努力。 This marks a significant step in combating dengue and highlights India's efforts in vaccine research and development.